Tue. Apr 13th, 2021
Venous Thromboembolism Pipeline


DelveInsight has launched a new report on Venous Thromboembolism Pipeline

Venous thromboembolism (VTE) is a disorder that includes deep vein thrombosis (DVT) and pulmonary embolism (PE). A deep vein thrombosis (DVT) occurs when a blood clot forms in a deep vein, usually in the lower leg, thigh, or pelvis. A deep vein thrombosis may occur if the flow of blood slows down in the body’s deep veins. A pulmonary embolism (PE) occurs when a clot breaks loose and travels through the bloodstream to the lungs.

Request for free sample copy- https://www.delveinsight.com/sample-request/venous-thromboembolism-pipeline-insight

Venous Thromboembolism Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of Venous Thromboembolism Pipeline products with detailed clinical profiles, key cross -competition, launch date along with product development activities.

Venous Thromboembolism Pipeline

The available therapeutics treatment options in Venous Thromboembolism Landscape focuses on breaking the clots and preventing further formation of clots. The dynamics of Venous Thromboembolism market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world.

Venous Thromboembolism Symptoms

The signs and symptoms of VTE are not the same for everyone. Sometimes VTE does not because symptoms until serious complications occur. In other cases, deep vein thrombosis causes swelling or discomfort near the blood clot. Pulmonary embolism can cause chest pain and difficulty breathing. Pulmonary embolism can be a life-threatening condition.

Marketed drugs included in the report

  • Fragmin: Eisai
  • Bevyxxa: Portola Pharmaceuticals
  • Savaysa: Daiichi Sankyo

Emerging drugs included in the report

  • SelK2: Tetherex Pharmaceuticals
  • ONO-7684: Ono Pharmaceutical Co. Ltd

Venous Thromboembolism Report Scope

  • The Venous Thromboembolism report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Venous Thromboembolism across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Venous Thromboembolism therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Venous Thromboembolism research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Venous Thromboembolism

Request for free sample copy- https://www.delveinsight.com/sample-request/venous-thromboembolism-pipeline-insight

Table of content

  1. Report Introduction
  2. Venous Thromboembolism
  3. Venous Thromboembolism Current Treatment Patterns
  4. Venous Thromboembolism – DelveInsight’s Analytical Perspective
  5. Venous Thromboembolism Therapeutic Assessment
  6. Venous Thromboembolism Late Stage Products (Phase-III)
  7. Venous Thromboembolism Mid Stage Products (Phase-II)
  8. Early Stage Products (Phase-I)
  9. Pre-clinical Products and Discovery Stage Products
  10. Inactive Products
  11. Dormant Products
  12. Venous Thromboembolism Discontinued Products
  13. Venous Thromboembolism Product Profiles
  14. Venous Thromboembolism Key Companies
  15. Venous Thromboembolism Key Products
  16. Dormant and Discontinued Products
  17. Venous Thromboembolism Unmet Needs
  18. Venous Thromboembolism Future Perspectives
  19. Venous Thromboembolism Analyst Review
  20. Appendix
  21. Report Methodology

Related Reports

View Recent Reports

Check our latest articles on blog–  DelveInsight Blog


By sthakur